Correction: Balleza Alejandri et al. Empagliflozin and Dapagliflozin Improve Endothelial Function in Mexican Patients with Type 2 Diabetes Mellitus: A Double-Blind Clinical Trial. J. Cardiovasc. Dev. Dis. 2024, 11, 182
Authors:
- Luis Ricardo Balleza AlejandriLALuis Ricardo Balleza Alejandri
- Fernando Grover PáezFPFernando Grover Páez
- Erick González CamposECErick González Campos
- Carlos G. Ramos BecerraCBCarlos G. Ramos Becerra
- Ernesto Germán Cardona MuñózEMErnesto Germán Cardona Muñóz
- Sara Pascoe GonzálezSGSara Pascoe González
- María Guadalupe Ramos ZavalaMZMaría Guadalupe Ramos Zavala
- Africa Samantha Reynoso RoaARAfrica Samantha Reynoso Roa
- Daniel Osmar Suárez RicoDaniel Osmar Suárez Rico
- Alberto Beltrán RamírezAlberto Beltrán Ramírez
- Jesús Jonathan García GalindoJesús Jonathan García Galindo
- David Cardona MüllerDMDavid Cardona Müller
Open Access
- 9 October 2024
- journal article
- correction
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 11 (10) , 314
Abstract
No abstract availableKeywords
This publication has 1 reference indexed in Scilit:
- Empagliflozin and Dapagliflozin Improve Endothelial Function in Mexican Patients with Type 2 Diabetes Mellitus: A Double-Blind Clinical TrialJournal of Cardiovascular Development and Disease, 2024